In July 2025, the European Commission, together with the European Medicines Agency and the Pharmaceutical Inspection Co-operation Scheme, launched a public consultation on the revision of Chapter 4 of the European Good Manufacturing Practice guidelines. This chapter governs documentation management across the pharmaceutical industry, and its revision, carried out alongside updates to Annex 11 on computerised systems and the creation of the new Annex 22 on artificial intelligence in GMP environments, marks one of the most significant regulatory shifts the sector has seen in decades.

How we got here

Although European GMP guidelines have existed since the 1960s, documentation management had not undergone a deep structural revision for many years. Traditional records, including batch documentation, quality control sheets, and manufacturing manuals, were governed by basic principles of integrity and traceability, but without fully addressing the growing digitalisation of pharmaceutical processes.

In November 2022, the European Commission published a concept paper on the revision of Annex 11, initiating the formal process of updating critical GMP elements to bring them in line with modern technologies. After more than two years of preliminary work, draft versions of Chapter 4, the revised Annex 11, and the new Annex 22 were published in July 2025, opening a three-month public consultation period that concluded in October 2025. During that period, companies, industry associations, compliance experts, and other stakeholders submitted comments and suggestions that will influence the final version, which is expected to be published in 2026.

What changes with the revision of Chapter 4

The core of this update is data integrity and digital document governance. While the previous version of Chapter 4 already addressed documentation requirements, the revision significantly expands and modernises its scope across several key areas.

For the first time, an explicit risk management approach is incorporated into documentation practices. This allows companies to prioritise controls according to the criticality of each process and the sensitivity of the data involved, rather than applying uniform requirements regardless of context.

The revision also acknowledges that records today exist in physical, electronic, and hybrid formats, and establishes that all of them must remain complete, legible, accessible, and traceable throughout their full lifecycle. This is a meaningful shift from a regulatory framework that was originally designed around paper-based documentation.

On the question of electronic signatures and electronic records, the revision provides precise definitions and requirements for how these must be managed to ensure they are legally valid, auditable, and secure. The framework is aligned with ALCOA++ data integrity principles, which cover the requirements for documentation to be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available.

Finally, the Chapter 4 update has been designed in direct alignment with the revised Annex 11 on computerised systems. This creates an integrated regulatory framework in which digital documentation is managed in coordination with the control, monitoring, and validation systems that govern computerised processes in pharmaceutical manufacturing.

Why this revision matters for the industry

The impact of this update goes beyond compliance. By raising the standard for data integrity and traceability, the revision strengthens the foundation on which the quality and safety of medicinal products depends. It also prepares the regulatory ground for the integration of artificial intelligence and advanced data analytics in GMP environments, which is addressed directly in the new Annex 22.

In practical terms, the revision requires companies to implement more robust data governance and record control procedures. This includes periodic audits of documentation systems, validation of digital platforms, and lifecycle management of records from creation through to archiving and deletion.

For pharmaceutical companies that have already invested in digital transformation, this revision is an opportunity to align existing systems with a clearer and more demanding regulatory framework. For those that have not yet made that transition, it is a signal that the direction of travel in GMP regulation is firmly toward digital, risk-based, and data-driven documentation management.

The final version of the revised Chapter 4, along with the updated Annex 11 and the new Annex 22, is expected to be published in 2026. Companies that begin preparing now will be better positioned to adapt without disrupting their operations.